Acta Neurologica Belgica

, Volume 115, Issue 1, pp 77–79 | Cite as

Ventricular arrhythmia in a male MS patient on fingolimod

  • Vincent van PeschEmail author
  • Sébastien Marchandise
  • Souraya El Sankari
  • Christian Sindic
Letter to the Editor


Fingolimod is a structural analogue of sphingosine-1-phosphate approved as the first oral agent for the treatment of relapsing remitting multiple sclerosis. Apart from its effects on the immune system, fingolimod is known to have a negative chronotropic effect upon first dose intake. Little is known, however, about the longer term potential effects of fingolimod on ventricular rhythm. We document an increase in ventricular premature complexes (VPCs) in a patient on fingolimod who experienced three unexplained syncopes while on treatment. VPC frequency decreased significantly and no further syncopes occurred after stopping fingolimod. This suggests that, in predisposed patients, fingolimod might potentiate the occurrence of ventricular arrhythmia.

A 49-year-old male patient with relapsing–remitting multiple sclerosis was included in a 4-month phase 3b trial, involving fingolimod [ 1]. The patient provided written informed consent both for trial inclusion and this case report. At...


Multiple Sclerosis Fingolimod Cardiac arrhythmia Safety 


Conflicts of interest

V. van Pesch has received travel grants and honoraria for consultancy and lectures from from Biogen Idec, Bayer Schering, Sanofi Aventis, Genzyme, Merck Serono and Novartis Pharma. C. Sindic has received honoraria for consultancy and lectures, and educational and research grants, from Bayer-Schering, Biogen Idec, GSK Biological Vaccines, Merck Serono, Novartis, Sanofi-Aventis and Teva. S. El Sankari has received consultancy fees from Biogen Idec and travel grants from Biogen Idec, Bayer Schering, Sanofi Aventis, Genzyme, Merck Serono and Novartis Pharma. S. Marchandise has nothing to disclose.


  1. 1.
    Gold R, Comi G, Palace J, Siever A, Gottschalk R, Bijarnia M, von Rosenstiel P, Tomic D, Kappos L (2013) Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study. J Neurol. doi: 10.1007/s00415-013-7115-8 PubMedCentralGoogle Scholar
  2. 2.
    Koyrakh L, Roman MI, Brinkmann V, Wickman K (2005) The heart rate decrease caused by acute FTY720 administration is mediated by the G protein-gated potassium channel I. Am J Transplant 5(3):529–536. doi: 10.1111/j.1600-6143.2005.00754.x CrossRefPubMedGoogle Scholar
  3. 3.
    DiMarco J (2012) Fingolimod treatment initiation experience: cardiac and holter electrocardiogram findings from three phase 3 studies. Mult Scler J 18(4 suppl):55–277. doi: 10.1177/1352458512459019 CrossRefGoogle Scholar
  4. 4.
    Bakshi R, Karan R. Novartis Pharma, data on fileGoogle Scholar
  5. 5.
    Fazekas F (2012) Fingolimod in the treatment algorithm of relapsing remitting multiple sclerosis: a statement of the Central and East European (CEE) MS Expert Group. Wien Med Wochenschr 162(15–16):354–366. doi: 10.1007/s10354-012-0123-y CrossRefPubMedCentralPubMedGoogle Scholar
  6. 6.
    Lindsey JW, Haden-Pinneri K, Memon NB, Buja LM (2012) Sudden unexpected death on fingolimod. Mult Scler 18(10):1507–1508. doi: 10.1177/1352458512438456 CrossRefPubMedGoogle Scholar

Copyright information

© Belgian Neurological Society 2014

Authors and Affiliations

  • Vincent van Pesch
    • 1
    Email author
  • Sébastien Marchandise
    • 2
  • Souraya El Sankari
    • 1
  • Christian Sindic
    • 1
  1. 1.Neurology DepartmentCliniques Universitaires St-LucBrusselsBelgium
  2. 2.Cardiology DepartmentCliniques Universitaires St-LucBrusselsBelgium

Personalised recommendations